NO20070250L - S-Tenatoprazol-natriummonohydratsalt og dennes anvendelse i form av en protonpumpe-inhibitor - Google Patents

S-Tenatoprazol-natriummonohydratsalt og dennes anvendelse i form av en protonpumpe-inhibitor

Info

Publication number
NO20070250L
NO20070250L NO20070250A NO20070250A NO20070250L NO 20070250 L NO20070250 L NO 20070250L NO 20070250 A NO20070250 A NO 20070250A NO 20070250 A NO20070250 A NO 20070250A NO 20070250 L NO20070250 L NO 20070250L
Authority
NO
Norway
Prior art keywords
proton pump
pump inhibitor
monohydrate salt
sodium monohydrate
tenatoprazole sodium
Prior art date
Application number
NO20070250A
Other languages
English (en)
Inventor
Avraham Cohen
Herve Ficheux
Michel Homerin
Francois Schutze
Suzy Charbit
Frederic Martinet
Original Assignee
Sidem Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sidem Pharma Sa filed Critical Sidem Pharma Sa
Publication of NO20070250L publication Critical patent/NO20070250L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse angår det monohydrerte natriumsaltet av S-tenatoprazol, representert ved den følgende formel og anvendelsen av dette i terapi for behandling av sykdommer i fordøyelsessystemet.
NO20070250A 2004-06-17 2007-01-15 S-Tenatoprazol-natriummonohydratsalt og dennes anvendelse i form av en protonpumpe-inhibitor NO20070250L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0406617A FR2871800B1 (fr) 2004-06-17 2004-06-17 Sel de sodium monohydrate du s-tenatoprazole et application en therapeutique
PCT/FR2005/001528 WO2006005853A1 (fr) 2004-06-17 2005-06-17 Sel de sodium monohydrate du s-tenatoprazole et application en tant qu'inhibiteur de la pompe a protons

Publications (1)

Publication Number Publication Date
NO20070250L true NO20070250L (no) 2007-03-14

Family

ID=34948439

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070250A NO20070250L (no) 2004-06-17 2007-01-15 S-Tenatoprazol-natriummonohydratsalt og dennes anvendelse i form av en protonpumpe-inhibitor

Country Status (23)

Country Link
US (1) US7402593B2 (no)
EP (1) EP1664044B1 (no)
JP (1) JP5393028B2 (no)
KR (1) KR101174932B1 (no)
CN (1) CN101001858B (no)
AT (1) ATE369366T1 (no)
AU (1) AU2005261580C1 (no)
BR (1) BRPI0512151A (no)
CA (1) CA2568993C (no)
CY (1) CY1106950T1 (no)
DE (1) DE602005001918T2 (no)
DK (1) DK1664044T3 (no)
ES (1) ES2290921T3 (no)
FR (1) FR2871800B1 (no)
HK (1) HK1106246A1 (no)
IL (1) IL179813A (no)
MX (1) MXPA06014849A (no)
NO (1) NO20070250L (no)
NZ (1) NZ551866A (no)
PL (1) PL1664044T3 (no)
PT (1) PT1664044E (no)
RU (1) RU2376304C2 (no)
WO (1) WO2006005853A1 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
FR2909380B1 (fr) * 2006-12-04 2009-02-20 Sidem Pharma Sa Sa Conglomerats de sels de potassium de tenatoprazole
CN102276602A (zh) * 2011-06-30 2011-12-14 福建省福抗药业股份有限公司 一种泰妥拉唑盐的精制方法
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
JPH0643426B2 (ja) * 1986-07-25 1994-06-08 東京田辺製薬株式会社 イミダゾ〔４，５−ｂ〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤
JPH07157430A (ja) * 1993-10-12 1995-06-20 Tokyo Tanabe Co Ltd 安定化された医薬組成物
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
JPH08239381A (ja) * 1995-03-02 1996-09-17 Toa Eiyoo Kk 安定なベンズイミダゾール誘導体金属塩の溶媒和物及びその製造法並びにそれを含有する抗潰瘍剤
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
CA2417311C (en) * 2000-08-04 2012-07-10 Takeda Chemical Industries, Ltd. Crystalline alkali metal salts of lansoprazole and their production and use
WO2002062786A1 (en) * 2001-02-02 2002-08-15 Teva Pharmaceutical Industries Ltd. Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1h-benzimidazoles
CN1453278A (zh) * 2002-04-23 2003-11-05 中国人民解放军军事医学科学院放射医学研究所 一种拉唑类化合物及其制备方法与应用
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
FR2845916B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
BRPI0310118B1 (pt) * 2002-12-06 2015-10-20 Altana Pharma Ag processo para a preparação de inibidores de bomba de próton (ppi) opticamente puro possuindo uma estrutura de sulfinila
FR2848555B1 (fr) * 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
US7507746B2 (en) * 2003-02-24 2009-03-24 Mitsubishi Pharma Corporation Enantiomer of tenatoprazole and the use thereof in therapy
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
JP2006523201A (ja) * 2003-03-28 2006-10-12 シデム ファーマ スルホキシド誘導体をエナンチオ選択的に調製する方法

Also Published As

Publication number Publication date
CN101001858B (zh) 2012-03-14
IL179813A0 (en) 2007-05-15
AU2005261580C1 (en) 2011-06-16
JP2008502665A (ja) 2008-01-31
BRPI0512151A (pt) 2008-02-12
DE602005001918D1 (de) 2007-09-20
MXPA06014849A (es) 2007-03-23
PL1664044T3 (pl) 2007-12-31
CY1106950T1 (el) 2012-09-26
DK1664044T3 (da) 2007-12-27
WO2006005853A1 (fr) 2006-01-19
FR2871800A1 (fr) 2005-12-23
AU2005261580B2 (en) 2011-02-03
FR2871800B1 (fr) 2006-08-25
JP5393028B2 (ja) 2014-01-22
KR20070045194A (ko) 2007-05-02
US7402593B2 (en) 2008-07-22
ES2290921T3 (es) 2008-02-16
CN101001858A (zh) 2007-07-18
IL179813A (en) 2011-01-31
NZ551866A (en) 2010-07-30
ATE369366T1 (de) 2007-08-15
PT1664044E (pt) 2007-11-19
DE602005001918T2 (de) 2008-04-24
EP1664044A1 (fr) 2006-06-07
US20070179176A1 (en) 2007-08-02
RU2007101521A (ru) 2008-07-27
CA2568993A1 (fr) 2006-01-19
RU2376304C2 (ru) 2009-12-20
EP1664044B1 (fr) 2007-08-08
CA2568993C (fr) 2013-12-17
AU2005261580A1 (en) 2006-01-19
KR101174932B1 (ko) 2012-08-20
HK1106246A1 (en) 2008-03-07

Similar Documents

Publication Publication Date Title
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
IL203448A (en) History of azabiphenylaminobenzoic acid for use in the treatment or prevention of a pathological condition or disease susceptible to reduction by dhodh inhibition and medicinal preparations containing them
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
ZA200707009B (en) Multimers of pyrimidinone derivatives and their use as human neutrophil elastate inhibitors
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
NO20090052L (no) Nye forbindelser
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
EA201170521A1 (ru) Новые соединения
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
NO20072461L (no) Fremstilling og anvendelse av bifenyl-4-yl-karbonylaminosyre derivater for behandling av fedme
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
EA200970946A1 (ru) Комбинированная терапия антикоагулирующего средства с соединением, которое действует как ингибитор фактора ха
IS2696B (is) Setin 2-amínótetralín fyrir meðhöndlunina á geðdeyfð
EA200802329A1 (ru) Производные триазола ii
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
ECSP055844A (es) Nuevos compuestos triciclicos
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
UY29859A1 (es) Derivados de 1-amino-isiquinolina,su preparación y su aplicación terapéutica
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
NO20070250L (no) S-Tenatoprazol-natriummonohydratsalt og dennes anvendelse i form av en protonpumpe-inhibitor
AR077371A1 (es) DERIVADOS DE PIRAZOL, SU PREPARACIoN Y SU APLICACIoN EN LA TERAPIA DEL CÁNCER

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application